Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2008

View Archived Issues

Almirall releases positive results for aclidinium bromide in the treatment of COPD

Boehringer Ingelheim launches direct thrombin inhibitor Pradaxa

Tekmira and Protiva enter share purchase agreement

Discovery Labs to meet with FDA to clarify items in approvable letter for Surfaxin in RDS

Gilead acquires Navitas' cicletanine for pulmonary arterial hypertension

Kiadis Pharma enters collaboration with Julius-Maximilians University for ATIR in GVHD

CureVac enters licensing agreement with LICR for three tumor-associated antigens

Medicines Company has announced results from VELOCITY phase III trial of Cleviprex

Repros Therapeutics releases findings from 1-year extension safety study of Proellex

Phase I study of seliciclib and Tarceva in advanced cancers scheduled to begin

PharmaIN and PNRI enter collaboration to study PGC GLP-1 in combination with Januvia

New agents for diabetes and other endocrine-related disorders reported in recent patents

New therapeutic agents for cardiovascular disorders disclosed in recent patent literature

Recent Janssen and Daiichi Sankyo patents impart novel antithrombotic agents

Early evidence of activity with ABT-263 in treating lymphoid malignancies

Atrium to initiate phase I clinical trial of Cinatra voclosporin coated coronary stent system

Patient death in phase I trial of StemCells' HuCNS-SC due to natural progression of disease

Kissei licenses KGT development and sales rights in Japan to GlaxoSmithKline

Enzon reports phase I results of EZN-2208 and EZN-2232

Pharmacopeia focuses resources on later-stage discovery programs

Phase III rivaroxaban trial shows superiority to enoxaparin in venous blood clots

Cardioprotective activity of novel adenosine 1 receptor agonist

Shareholders of CeNeS vote for acquisition by Paion

TransMolecular initiates phase I unlabeled TM-601 trial in malignant glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...